Royalty Pharma (RPRX) Competitors $36.24 +0.51 (+1.43%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$36.24 +0.00 (+0.01%) As of 09/19/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RPRX vs. ZTS, JAZZ, CORT, PRGO, SUPN, PCRX, NKTR, OMER, ASMB, and CPIXShould you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include Zoetis (ZTS), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceuticals" industry. Royalty Pharma vs. Its Competitors Zoetis Jazz Pharmaceuticals Corcept Therapeutics Perrigo Supernus Pharmaceuticals Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Royalty Pharma (NASDAQ:RPRX) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership and earnings. Which has more volatility and risk, RPRX or ZTS? Royalty Pharma has a beta of 0.58, suggesting that its stock price is 42% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Do institutionals & insiders have more ownership in RPRX or ZTS? 54.4% of Royalty Pharma shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor RPRX or ZTS? In the previous week, Zoetis had 28 more articles in the media than Royalty Pharma. MarketBeat recorded 41 mentions for Zoetis and 13 mentions for Royalty Pharma. Zoetis' average media sentiment score of 1.61 beat Royalty Pharma's score of 0.90 indicating that Zoetis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 40 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts rate RPRX or ZTS? Royalty Pharma currently has a consensus price target of $48.00, indicating a potential upside of 32.45%. Zoetis has a consensus price target of $200.88, indicating a potential upside of 37.75%. Given Zoetis' higher possible upside, analysts clearly believe Zoetis is more favorable than Royalty Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Royalty Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Zoetis 0 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.56 Is RPRX or ZTS more profitable? Royalty Pharma has a net margin of 44.23% compared to Zoetis' net margin of 27.83%. Zoetis' return on equity of 56.90% beat Royalty Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Royalty Pharma44.23% 25.54% 14.11% Zoetis 27.83%56.90%19.54% Is RPRX or ZTS a better dividend stock? Royalty Pharma pays an annual dividend of $0.88 per share and has a dividend yield of 2.4%. Zoetis pays an annual dividend of $2.00 per share and has a dividend yield of 1.4%. Royalty Pharma pays out 50.9% of its earnings in the form of a dividend. Zoetis pays out 34.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Royalty Pharma has increased its dividend for 5 consecutive years and Zoetis has increased its dividend for 14 consecutive years. Which has better valuation and earnings, RPRX or ZTS? Zoetis has higher revenue and earnings than Royalty Pharma. Royalty Pharma is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoyalty Pharma$2.26B9.33$858.98M$1.7320.95Zoetis$9.26B6.98$2.49B$5.8125.10 SummaryZoetis beats Royalty Pharma on 14 of the 20 factors compared between the two stocks. Get Royalty Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RPRX vs. The Competition Export to ExcelMetricRoyalty PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.13B$3.14B$5.77B$10.45BDividend Yield2.43%2.35%5.61%4.56%P/E Ratio20.9520.9180.5026.82Price / Sales9.33262.05455.1691.38Price / Cash8.6446.4637.6661.43Price / Book2.069.6015.756.39Net Income$858.98M-$53.22M$3.30B$271.80M7 Day Performance-0.33%3.11%5.35%3.51%1 Month Performance-0.19%6.23%7.28%9.58%1 Year Performance31.59%11.02%80.79%28.53% Royalty Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RPRXRoyalty Pharma4.8853 of 5 stars$36.24+1.4%$48.00+32.5%+31.6%$21.13B$2.26B20.9580High Trading VolumeZTSZoetis4.8603 of 5 stars$151.88-0.9%$202.43+33.3%-24.3%$67.31B$9.26B26.1413,800Positive NewsJAZZJazz Pharmaceuticals4.4632 of 5 stars$129.85+0.3%$178.67+37.6%+15.8%$7.86B$4.09B-19.292,800Positive NewsCORTCorcept Therapeutics4.7786 of 5 stars$71.23+2.7%$134.50+88.8%+90.6%$7.51B$675.04M63.04300Positive NewsPRGOPerrigo4.7992 of 5 stars$22.31-1.5%$33.00+47.9%-21.8%$3.07B$4.37B-38.468,379Analyst DowngradeSUPNSupernus Pharmaceuticals2.8915 of 5 stars$45.82-0.4%$43.00-6.2%+44.7%$2.57B$661.82M39.84580Analyst UpgradePCRXPacira BioSciences3.2799 of 5 stars$26.74+1.1%$30.83+15.3%+83.5%$1.20B$700.97M-9.62720Positive NewsNKTRNektar Therapeutics4.1444 of 5 stars$44.33+10.3%$88.33+99.3%+182.8%$843.11M$74.93M-5.04220Trending NewsAnalyst ForecastHigh Trading VolumeOMEROmeros3.794 of 5 stars$4.21+1.0%$18.00+327.6%+6.6%$286.53MN/A-2.00210Analyst UpgradeASMBAssembly Biosciences3.448 of 5 stars$23.32-2.1%$41.33+77.2%+25.9%$178.86M$28.52M-4.18100Positive NewsHigh Trading VolumeCPIXCumberland Pharmaceuticals0.2991 of 5 stars$3.31flatN/A+158.2%$49.52M$37.87M-15.0580Positive News Related Companies and Tools Related Companies Zoetis Competitors Jazz Pharmaceuticals Competitors Corcept Therapeutics Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RPRX) was last updated on 9/21/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Royalty Pharma PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Royalty Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.